Drug Trial Radar · NCT01634061
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Last checked: Nov 19, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Sep 2012
Primary completion
Jul 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.
Conditions
- Castration-resistant Prostate Cancer
Interventions
BEZ235Drug
BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
BKM120Drug
BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
BEZ235Drug
BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
BKM120Drug
BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs)Time frame: from days 1-35 in BEZ235/abiraterone acetate arm and from days 1-28 in BKM120/abiraterone acetate arm
- Prostate specific antigen (PSA) decline ≥ 30%Time frame: At week 12 or later after treatment discontinuation
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center SC
Los Angeles, California
Hackensack University Medical Center Hackensack Univ
Hackensack, New Jersey
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Wilrijk, Belgium
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.